feedback

Course Director

Professor David I. Marks
Professor David I. Marks

University Bristol NHS Foundation Trust
Bristol, United Kingdom

Faculty

Farhad Ravandi
Farhad Ravandi, MD

The University of Texas MD Anderson Cancer Center
Houston, Texas

Matthias Stelljes
Matthias Stelljes, MD

University of Münster
Albert-Schweitzer-Campus
Münster, Germany

Accredited by

Medical Learning Institute, Inc.

View Activity Materials

Activity Description

In this new CME/MOC-accredited video activity Professor David I. Marks, Farhad Ravandi, MD, and Matthias Stelljes, MD, give insights on the evidence behind the emergence of antibody therapy and its use in conjunction with HSCT in AML and ALL. These scientific MasterClass sessions are paired with a case-centered segment that illustrates therapeutic nuances such as the identification of transplant-eligible patients who may benefit from antibody-enhanced treatment protocols and the management of safety considerations unique to the use of antibodies in HSCT populations.

Target Audience

This activity has been designed to meet the educational needs of BMT specialists, hematologists, oncologists, and other clinicians involved in the management of acute leukemia.

Educational Objectives

Upon completion of this activity, participants should be better able to:
  • Cite current guidelines for transplant eligibility and the use of novel therapeutics as induction/consolidation, pretransplant conditioning, or other roles in conjunction with transplant in the acute leukemia setting
  • Summarize updated evidence surrounding innovative antibody-based approaches to induction/consolidation, conditioning, or post-HSCT therapy in patients with AML or ALL
  • Recommend evidence-based regimens with novel components as part of a treatment plan that includes allogeneic HSCT for patients with AML or ALL
  • Manage safety considerations related to the use of antibody therapy in transplant-eligible populations with acute leukemia

Providership, Credit, and Support


This CME/MOC activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

This activity is supported by an educational grant from Pfizer.

Physician Continuing Medical Education

ACCMEThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit™ into European CME credit (ECMEC) should contact the UEMS ( www.uems.eu).

MOC Statement

MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 Medical Knowledge MOC points and 1.5 Patient Safety MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS). Blinded individual or aggregated participant data may be shared with the funder of the activity.

Faculty Disclosures

Chair
Professor David I. Marks
Professor of Haematology and Stem Cell Transplantation
University Bristol NHS Foundation Trust
Bristol, United Kingdom

Professor David I. Marks has a financial interest/relationship or affiliation in the form of:
Honoraria from Amgen Inc. and Pfizer.

Faculty
Farhad Ravandi, MD
Janiece and Stephen A. Lasher Professor of Medicine
Chief, Section of Developmental Therapeutics
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Farhad Ravandi, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; Astellas Pharma US, Inc.; AstraZeneca; Celgene Corporation; and Jazz Pharmaceuticals, Inc.
Grant/Research Support from AbbVie Inc.; Amgen Inc.; Jazz Pharmaceuticals, Inc.; and Xencor.
Honoraria from AbbVie Inc.; Amgen Inc.; Astellas Pharma US, Inc.; AstraZeneca; Celgene Corporation; Jazz Pharmaceuticals, Inc.; Pfizer Inc.; and Xencor.

Matthias Stelljes, MD
Professor of Medicine
Department of Medicine/Hematology and Oncology
University of Münster
Albert-Schweitzer-Campus
Münster, Germany

Matthias Stelljes, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; Astellas Pharma Inc.; Bristol Myers Squibb; Gilead Sciences, Inc.; Jazz Pharmaceuticals, Inc.; medac Pharma; Merck Sharp & Dohme Corp.; Novartis AG; and Pfizer, Inc.
Grant/Research Support from Pfizer, Inc.
Speaker honoraria from Amgen, Inc.; Bristol Myers Squibb; Chugai; Jazz Pharmaceuticals, Inc.; Medac Pharma; Merck Sharp & Dohme Corp.; Novartis AG; and Pfizer, Inc.

Planning Committee Disclosures

The planners from Medical Learning Institute, Inc., the accredited provider, and PeerView Institute for Medical Education, the joint provider, do not have any financial relationships with an ACCME-defined commercial interest related to the content of this accredited activity during the past 12 months unless listed below.

Content/Peer Reviewer Disclosures

The following Content/Peer Reviewers have nothing to disclose:

Christopher Jakubowski, MD
Janice Trainor-Tellier, MSN, RN

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this accredited activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain MOC credit. There are no prerequisites and there is no fee to participate in this activity or to receive MOC credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

About This CME/MOC Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2020, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.